Hexagon Nutrition

Hexagon Nutrition (operating as Q-Line Biotech) has been providing diagnostic equipment and IVD products since 2013, establishing its brand over 12 years through dedicated R&D and quality assurance. The company focuses on core segments including Clinical Chemistry, Haematology, Immunodiagnostics, and Molecular Diagnostics, as well as Point-of-Care (POC) devices.

During the Covid-19 pandemic, the company successfully diversified its portfolio by developing RT-PCR, RNA Extraction, and VTM kits through technical collaborations with third-party institutes. This agility allowed them to expand their reach within the diagnostic healthcare ecosystem.

The business model leverages both indigenous manufacturing and international technical collaborations to ensure products adhere to global quality standards. Their product range is distributed directly and through a network of distributors to medical colleges and hospitals.

As of March 31, 2026, the company operates with a workforce of 362 permanent employees and 223 contract employees. A significant focus on innovation is evident, with 19 dedicated personnel in R&D laboratories, representing over 5% of the total permanent staff.

The company's operational scale is reflected in its growing asset base, which reached ₹561.34 crore by December 2025, supporting its expansion into diverse reagent formulations and diagnostic equipment.

The IPO seeks to mobilize ₹214.48 crore through the issuance of 6,253,200 equity shares priced between ₹326 and ₹343 per share. The issue is scheduled to open on May 21, 2026, and close on May 25, 2026, with listing on the NSE SME Emerge platform. The minimum application lot size is 800 shares.

Proceeds from the fresh issue are earmarked for strategic growth and liability management, with ₹93.50 crore allocated for working capital and ₹90.00 crore dedicated to the repayment or prepayment of borrowings, with the remainder for general corporate purposes.

Financial performance shows top-line growth, with revenue increasing from ₹184.81 crore in FY23 to ₹322.58 crore in FY25. However, the bottom line has been inconsistent; PAT dropped to ₹28.13 crore in FY25 due to accounting adjustments, before jumping to ₹38.69 crore in the first 9 months of FY26, raising sustainability concerns.

Valuation is a critical point of debate as the company has no listed peers for a direct comparison. Based on FY25 earnings, the P/E stands at 28.44, while the 9M-FY26 'super earnings' put the P/E at 15.51. The issue is priced at a P/BV of 2.44 based on an NAV of ₹140.81.

Key strengths include a strong R&D focus and successful diversification during the pandemic. However, risks include high overall borrowings of ₹242.57 crore and contingent liabilities totaling ₹61.64 crore as of December 2025.

For investors, the IPO presents a mix of high-growth potential in the IVD sector and significant financial risks. While long-term prospects may be attractive for those monitoring the healthcare diagnostic space, the 'fully priced' nature of the issue suggests limited immediate upside.